Positive topline results from phase 2 VVN461 trial for non-infectious anterior uveitis
VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, showcasing safety and efficacy.
NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope for innovative retinal therapies.
Neuro-ophthalmologic evaluation crucial in differentiating benign from life-threatening diplopia
Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions.
(Part 2) From ophthalmology’s lockdown to lasting change: The pandemic habits that stuck
From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption
(Part 1) From ophthalmology’s lockdown to lasting change: Five Aprils ago
Ophthalmologists reflect on the transformative impact of COVID-19, highlighting adaptations in patient care, safety protocols, and the rise of telemedicine.
ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)
ENTOD Pharmaceuticals launches Myatro XL, a 0.05% atropine eye drop, to effectively slow myopia progression in children, available by prescription in 2025.
Bausch + Lomb identifies issue in enVista platform, returns product to market
Bausch + Lomb addresses recent IOL recall, ensuring safety with enhanced protocols and returning enVista lenses to market after thorough investigation.
Eye care industry leaders meet at White House to discuss tariff implications
Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.
Diagnosis and disease evolution of uveitis: A 10-year look back
Characteristics of dry eye disease in patients with autoimmune diseases
Pediatric ocular surface reconstruction: Managing lesion excision challenges
This population requires careful attention from diagnosis through the entire postoperative process.
Potential biomarkers of primary open-angle glaucoma in patient serum in Nigeria
When the world went virtual: How ophthalmology’s conferences stayed on track
Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis
Self-reported vision problems tied to increased sleep dysfunction in older adults
Researchers develop virus-like particle to enhance editing proteins causing inherited eye diseases
Regeneron announces FDA issues CRL for aflibercept 8 mg (Eylea HD) sBLA
The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.
Prevent Blindness urges West Virginia State Legislature to reject bill removing newborn eye infection protection
The affected mandate requires that all newborns receive erythromycin ointment applied to their eyes after birth, which helps prevent ophthalmia neonatorum.
Unveiling genetic distinctions between reticular pseudodrusen and drusen
Insights from a genome-wide association study identify novel genetic loci
Zhaoke enrolls first patient in phase 3 trial of cyclosporine ophthalmic gel for dry eye
CsA Ophthalmic Gel is an innovative cyclosporine gel being developed by Zhaoke in China for the treatment of moderate to severe DED.
Using retinal images to classify metabolic syndrome
Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”
AI-assisted biomarker segmentation offers precision in nAMD disease monitoring
Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.
CIME 2025 unveils a galaxy of innovation in modern eye care
Neda Shamie, MD, previews the May 4 conference, where a faculty of ophthalmologists and optometrists will explore the latest advancements and controversies.
50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs
Celebrating a half-century of progress with Ophthalmology Times.
Companies announce presentations at upcoming 2025 ARVO Annual Meeting
The annual ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.
BVI Medical receives 510(k) FDA clearance for glaucoma surgical system
Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.
Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening the dosing schedule to include every-4-week dosing across approved indications.
ISO issues new standards for presbyopia-correcting IOL classification
Updated guidelines characterize IOLs by functional performance over optical design.
Effect of race on visual outcomes in DME treated with ranibizumab
The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.
FDA grants RMAT designation to Atsena Therapeutics' gene therapy for XLRS
ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there currently are no approved treatments.
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA
A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.
